These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 10335903)
1. Troglitazone has no effect on red cell mass or other erythropoietic parameters. Young MM; Squassante L; Wemer J; van Marle SP; Dogterom P; Jonkman JH Eur J Clin Pharmacol; 1999 Apr; 55(2):101-4. PubMed ID: 10335903 [TBL] [Abstract][Full Text] [Related]
2. The effect of troglitazone on plasma homocysteine, hepatic and red blood cell S-adenosyl methionine, and S-adenosyl homocysteine and enzymes in homocysteine metabolism in Zucker rats. Fonseca V; Keebler M; Dicker-Brown A; Desouza C; Poirier LA; Murthy SN; McNamara DB Metabolism; 2002 Jun; 51(6):783-6. PubMed ID: 12037736 [TBL] [Abstract][Full Text] [Related]
3. Long-term cardiovascular effects of insulin sensitizer troglitazone on non-diabetic individuals with insulin resistance: double blind, prospective randomized study. Stakos DA; Schuster DP; Sparks EA; Wooley CF; Osei K; Boudoulas H J Cardiol; 2003 Apr; 41(4):183-90. PubMed ID: 12728539 [TBL] [Abstract][Full Text] [Related]
4. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients. Kumar S; Prange A; Schulze J; Lettis S; Barnett AH Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807 [TBL] [Abstract][Full Text] [Related]
5. Troglitazone treatment increases protein kinase B phosphorylation in skeletal muscle of normoglycemic subjects at risk for the development of type 2 diabetes. Meyer MM; Levin K; Grimmsmann T; Perwitz N; Eirich A; Beck-Nielsen H; Klein HH Diabetes; 2002 Sep; 51(9):2691-7. PubMed ID: 12196460 [TBL] [Abstract][Full Text] [Related]
6. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients. Cominacini L; Garbin U; Fratta Pasini A; Campagnola M; Davoli A; Foot E; Sighieri G; Sironi AM; Lo Cascio V; Ferrannini E Diabetes; 1998 Jan; 47(1):130-3. PubMed ID: 9421387 [TBL] [Abstract][Full Text] [Related]
8. Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase. Kobayashi J; Nagashima I; Hikita M; Bujo H; Takahashi K; Otabe M; Morisaki N; Saito Y Br J Clin Pharmacol; 1999 Apr; 47(4):433-9. PubMed ID: 10233209 [TBL] [Abstract][Full Text] [Related]
9. Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Kawai T; Takei I; Oguma Y; Ohashi N; Tokui M; Oguchi S; Katsukawa F; Hirose H; Shimada A; Watanabe K; Saruta T Metabolism; 1999 Sep; 48(9):1102-7. PubMed ID: 10484048 [TBL] [Abstract][Full Text] [Related]
10. Troglitazone: a review of its use in the management of type 2 diabetes mellitus. Plosker GL; Faulds D Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691 [TBL] [Abstract][Full Text] [Related]
11. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects. Frias JP; Yu JG; Kruszynska YT; Olefsky JM Diabetes Care; 2000 Jan; 23(1):64-9. PubMed ID: 10857970 [TBL] [Abstract][Full Text] [Related]
12. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Maggs DG; Buchanan TA; Burant CF; Cline G; Gumbiner B; Hsueh WA; Inzucchi S; Kelley D; Nolan J; Olefsky JM; Polonsky KS; Silver D; Valiquett TR; Shulman GI Ann Intern Med; 1998 Feb; 128(3):176-85. PubMed ID: 9454525 [TBL] [Abstract][Full Text] [Related]
13. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Azziz R; Ehrmann DA; Legro RS; Fereshetian AG; O'Keefe M; Ghazzi MN; Fertil Steril; 2003 Apr; 79(4):932-7. PubMed ID: 12749433 [TBL] [Abstract][Full Text] [Related]
14. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. Takagi T; Akasaka T; Yamamuro A; Honda Y; Hozumi T; Morioka S; Yoshida K J Am Coll Cardiol; 2000 Nov; 36(5):1529-35. PubMed ID: 11079654 [TBL] [Abstract][Full Text] [Related]
15. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T Diabet Med; 1996 Apr; 13(4):365-70. PubMed ID: 9162613 [TBL] [Abstract][Full Text] [Related]
16. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus. Johnson MD; Campbell LK; Campbell RK Ann Pharmacother; 1998 Mar; 32(3):337-48. PubMed ID: 9533065 [TBL] [Abstract][Full Text] [Related]
17. Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers. Cominacini L; Young MM; Capriati A; Garbin U; Fratta Pasini A; Campagnola M; Davoli A; Rigoni A; Contessi GB; Lo Cascio V Diabetologia; 1997 Oct; 40(10):1211-8. PubMed ID: 9349604 [TBL] [Abstract][Full Text] [Related]
18. Relationships between apolipoprotein(a) phenotype and increase of lipoprotein(a) by troglitazone. Matsumoto K; Miyake S; Yano M; Ueki Y; Tominaga Y Metabolism; 1999 Jan; 48(1):1-2. PubMed ID: 9920136 [TBL] [Abstract][Full Text] [Related]
19. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856 [TBL] [Abstract][Full Text] [Related]
20. Troglitazone, an insulin sensitizer, increases forearm blood flow in humans. Fujishima S; Ohya Y; Nakamura Y; Onaka U; Abe I; Fujishima M Am J Hypertens; 1998 Sep; 11(9):1134-7. PubMed ID: 9752901 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]